Fujifilm increases production capacity and establishes new process development facilities
$130M USD investment to support growing market demand.
Fujifilm will increase production capacity by investing about JPY14 billion ($130m) in the US and UK to expand the business of its BioCDMO Division.
In the US, at FUJIFILM Diosynth Biotechnologies Texas, LLC (FDBT), a JPY10 billion ($93m) cGMP production facility has been completed. This facility was built in part with funding from BARDA (Biomedical Advanced Research and Development Authority), an office of the US Department of Health and Human Services, and Fujifilm plans to invest an additional JPY3 billion ($28m) to outfit the facility with mammalian cell culture bioreactors. This facility will start operation at the beginning of 2018. FDBT was acquired by Fujifilm through FUJIFILM Diosynth Biotechnologies USA, Inc. (FDBU) in 2014. In March of this year, FDBT became a wholly owned subsidiary of FDBU exercising the option early included in the initial deal to take 100% ownership. In addition, a JPY1 billion ($9m) investment will be made to expand the Process Development capabilities at FUJIFILM Diosynth Biotechnologies UK Limited near to its Billingham, UK site. This facility is scheduled to be operational in summer of 2017.
The FDBT facility will be the manufacturing center of excellence for the company's Saturn Monoclonal Antibody Platform with an initial cell culture capacity of 6,000 L (3X 2000 L bioreactors). The design of the facility allows for future expansion that can accommodate up to 24,000L of upstream capacity to meet much needed customers' clinical and commercial demands. In the UK, the investments include the establishment of a dedicated Mammalian Cell Culture Center of Excellence. These laboratories span over 10,000 sq. ft. and are designed to incorporate the latest high-throughput technologies, including fully automated bioreactors and chromatography systems, to enable for rapid and efficient monoclonal antibody manufacturing process readiness. These assets will enable Fujifilm to provide 'best in class' facilities, technology and operational know how to the industry. They are also a key in our continuing commitment to develop future Medical Counter Measures and Pandemic Flu response candidates for our long term Partners the CIADM (Center for Innovation in Advanced Development and Manufacturing), BARDA and other third-party customers.
“FUJIFILM Diosynth Biotechnologies is committed to its vision of being Leaders in the Bio CDMO space,” said Steve Bagshaw, CEO, FUJIFILM Diosynth Biotechnologies, “Our commitment is to transform the CDMO business through innovation and with our great people — providing long term support to our partners fulfilling our core purpose as ‘Partners for Life - Advancing tomorrow's medicines’.”
Biopharmaceutical production requires the use of advanced manufacturing technologies and facilities for culturing, separation and purification. The number of companies outsourcing process development and manufacturing activities of biopharmaceuticals to CDMOs is increasing. The contract development and manufacturing market is projected to achieve growth of 8% per annum accordingly.
Fujifilm will continue to grow and expand its existing capabilities in addition to engaging in external collaborations to increase capacity, and it will further develop high efficiency and high productivity technology by combining group technologies, to continue to grow further the business. It is targeting sales of JPY100 billion in its BioCDMO business by 2023.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance